A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult
A phase 2 trial of Belantamab mafodotin, Dexamethasone, Pomalidomide in multiple myeloma, run by GlaxoSmithKline, now recruiting.
Overview
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) is a phase 2 interventional study registered as NCT07227311 by GlaxoSmithKline, with 200 participants planned, started 2026-04-15 and due to reach its primary completion in 2030-08-30. Interventions recorded: Belantamab mafodotin, Dexamethasone, Pomalidomide, Bortezomib, Carfilzomib. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAll Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo
Shares Belantamab mafodotin, Pomalidomide, Bortezomib, GSK.
- TrialA Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatme
Shares Belantamab mafodotin, Pomalidomide, GSK, Dexamethasone.
- TrialChina Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame
Shares Belantamab mafodotin, Bortezomib, GSK, Dexamethasone.
- TrialJapan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dex
Shares Belantamab mafodotin, Bortezomib, GSK, Dexamethasone.
- TrialSub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants Wi
Shares Belantamab mafodotin, Pomalidomide, GSK, Dexamethasone.
- TrialA Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
- TrialA Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
- TrialMagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.